Janus Henderson Group PLC Purchases 26,618 Shares of Medtronic plc (NYSE:MDT)

Janus Henderson Group PLC grew its position in shares of Medtronic plc (NYSE:MDT) by 0.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 3,877,532 shares of the medical technology company’s stock after acquiring an additional 26,618 shares during the quarter. Janus Henderson Group PLC’s holdings in Medtronic were worth $309,762,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MDT. Wealth Enhancement Advisory Services LLC lifted its position in Medtronic by 1.2% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 365,780 shares of the medical technology company’s stock worth $29,219,000 after buying an additional 4,371 shares during the last quarter. Graypoint LLC lifted its position in Medtronic by 7.6% in the fourth quarter. Graypoint LLC now owns 6,934 shares of the medical technology company’s stock worth $554,000 after buying an additional 490 shares during the last quarter. Czech National Bank lifted its position in Medtronic by 6.4% in the fourth quarter. Czech National Bank now owns 278,065 shares of the medical technology company’s stock worth $22,212,000 after buying an additional 16,786 shares during the last quarter. Clark & Stuart Inc bought a new stake in Medtronic in the fourth quarter worth $509,000. Finally, Fiduciary Alliance LLC bought a new stake in Medtronic in the fourth quarter worth $470,000. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MDT has been the subject of several research analyst reports. Robert W. Baird lifted their target price on Medtronic from $90.00 to $91.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. UBS Group lifted their target price on Medtronic from $85.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research report on Wednesday, February 19th. Citigroup upgraded Medtronic from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $92.00 to $107.00 in a research report on Tuesday, March 4th. Finally, Truist Financial cut their price target on Medtronic from $93.00 to $90.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Hold” and a consensus price target of $96.14.

Medtronic Price Performance

MDT opened at $83.47 on Monday. The business’s 50-day moving average is $86.76 and its two-hundred day moving average is $86.76. Medtronic plc has a 1 year low of $75.96 and a 1 year high of $96.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39. The firm has a market capitalization of $107.05 billion, a PE ratio of 25.37, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.03. The company had revenue of $8.29 billion for the quarter, compared to analyst estimates of $8.33 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. Research analysts anticipate that Medtronic plc will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 11th. Stockholders of record on Friday, March 28th were paid a dividend of $0.70 per share. The ex-dividend date was Friday, March 28th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.35%. Medtronic’s payout ratio is 85.11%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.